The estimated Net Worth of Georgia Erbez is at least $997 Mille dollars as of 22 September 2021. Ms Erbez owns over 10,300 units of Harpoon Therapeutics stock worth over $442,137 and over the last 8 years she sold HARP stock worth over $0. In addition, she makes $554,550 as Chief Financial Officer at Harpoon Therapeutics.
Ms has made over 8 trades of the Harpoon Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently she bought 10,300 units of HARP stock worth $83,430 on 22 September 2021.
The largest trade she's ever made was buying 68,000 units of Harpoon Therapeutics stock on 25 May 2017 worth over $89,760. On average, Ms trades about 11,887 units every 103 days since 2016. As of 22 September 2021 she still owns at least 19,215 units of Harpoon Therapeutics stock.
You can see the complete history of Ms Erbez stock trades at the bottom of the page.
Georgia L. Erbez is the Chief Financial Officer at Harpoon Therapeutics.
As the Chief Financial Officer of Harpoon Therapeutics, the total compensation of Ms Erbez at Harpoon Therapeutics is $554,550. There are 3 executives at Harpoon Therapeutics getting paid more, with Gerald McMahon having the highest compensation of $1,793,260.
Ms Erbez is 54, she's been the Chief Financial Officer of Harpoon Therapeutics since . There are 7 older and 5 younger executives at Harpoon Therapeutics. The oldest executive at Harpoon Therapeutics, Inc. is Gerald McMahon, 65, who is the President, Chief Executive Officer, Director.
Georgia's mailing address filed with the SEC is C/O COHERUS BIOSCIENCES, INC., 333 TWIN DOLPHIN DRIVE, SUITE 600, REDWOOD CITY, CA, 94065.
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt e Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Harpoon Therapeutics executives and other stock owners filed with the SEC include: